Effect of Mineralocorticoid Receptor Blockade in T2DEffect of Mineralocorticoid Receptor Blockade in T2D
Does spironolactone prevent heart disease in patients with type 2 diabetes? Diabetes (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 27, 2015 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

7 Reasons Women Lose Their Hair -- And 7 Treatments
Your ponytail is shrinking...or your part's getting wider...or there's more hair in the shower drain. Take heart -- you're not alone. According to New York City dermatologist Neil Sadick, MD, up to 80 percent of women will have some hair thinning in their lifetime, even if only temporarily. It's normal to shed 50 to 100 hairs a day, says NYC dermatologist Doris Day, MD. If you're losing more than that, a doctor's visit is in order. Here are some common causes and treatments. Cause: Genetics (the most likely culprit) Treatment: Minoxidil, the only topical ingredient that's FDA approved to regrow hair in women. Rogaine ha...
Source: Healthy Living - The Huffington Post - January 27, 2015 Category: Consumer Health News Source Type: news

Is Spironolactone a 'Savior' for Hemodialysis Patients?Is Spironolactone a 'Savior' for Hemodialysis Patients?
A new study found that spironolactone significantly reduced the risk for cardiovascular and cerebrovascular morbidity and death in hemodialysis patients, reports Dr Jeffrey Berns. Medscape Nephrology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 22, 2014 Category: Consumer Health News Tags: Nephrology Commentary Source Type: news

TOPCAT Analysis: Spironolactone Benefits HFPEF in Americas TOPCAT Analysis: Spironolactone Benefits HFPEF in Americas
A new post hoc analysis questions whether many patients entered into the trial in Russia and Georgia actually had heart failure. Heartwire (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 26, 2014 Category: Cardiology Tags: Cardiology News Source Type: news

As Used, Spironolactone Doesn't Cut 30-Day HF ReadmissionsAs Used, Spironolactone Doesn't Cut 30-Day HF Readmissions
It's probably a reflection of a long-recognized problem, say researchers; patients in clinical practice just aren't a lot like those in clinical trials. Heartwire (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 15, 2014 Category: Cardiology Tags: Cardiology News Source Type: news

spironolactone, Aldactone
Title: spironolactone, AldactoneCategory: MedicationsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 8/6/2014 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - August 6, 2014 Category: Cardiology Source Type: news

Spironolactone in Heart Failure? Yes, and Here's WhySpironolactone in Heart Failure? Yes, and Here's Why
Dr. Piña reviews a subgroup analysis from the TOPCAT trial, and explains why she thinks spironolactone has a role in many patients with heart failure. theheart.org on Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 14, 2014 Category: Consumer Health News Tags: Cardiology Commentary Source Type: news

Hyperkalemia Evident with Spironolactone in Resistant HTNHyperkalemia Evident with Spironolactone in Resistant HTN
A small study finds that 8% of resistant-hypertension patients treated with spironolactone developed hyperkalemia, including one who presented to the emergency department. Researchers advise doctors to monitor potassium levels when using the drug. Heartwire (Source: Medscape Nephrology Headlines)
Source: Medscape Nephrology Headlines - May 20, 2014 Category: Urology & Nephrology Tags: Cardiology News Source Type: news

Clinicians urged to consider spironolactone in HFPEF despite TOPCAT results
Clinicians have been urged to consider using spironolactone in their patients with heart failure and preserved ejection fraction (HFPEF) after a post-hoc analysis of the TOPCAT trial showed benefit in patients from the Americas. TOPCAT randomized 3445 patients with HFPEF to receive spironolactone, a mineralocorticoid receptor antagonist, at a dose of 15-45mg per day or placebo on top of usual care. Patients were recruited from 270 medical centres in 6 countries. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 18, 2014 Category: Science Source Type: news

Clinicians urged to consider spironolactone in HFPEF despite TOPCAT results
(European Society of Cardiology) Clinicians have been urged to consider using spironolactone in their patients with heart failure and preserved ejection fraction after a post-hoc analysis of the TOPCAT trial showed benefit in patients from the Americas.The research was presented today at the Heart Failure Congress 2014 in Athens, Greece. The Congress is the main annual meeting of the Heart Failure Association of the European Society of Cardiology. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 18, 2014 Category: Global & Universal Source Type: news

Clinicians urged to consider spironolactone in HFPEF despite TOPCAT results
Clinicians have been urged to consider using spironolactone in their patients with heart failure and preserved ejection fraction (HFPEF) after a post-hoc analysis of the TOPCAT trial showed benefit in patients from the Americas.  Professor Bertram Pitt said: “We’ve had many studies showing that ACE inhibitors, angiotensin receptor blockers, beta blockers and mineralocorticoid receptor blockers reduce mortality and hospitalisations in patients with heart failure and reduced ejection fraction (HFREF). But no studies have found a benefit of these medications in HFPEF patients.” ...
Source: ESC News and Press - May 14, 2014 Category: Cardiology Source Type: news

TOPCAT reveals regional differences in spironolactone effectiveness for HFpEF
Adding spironolactone to existing treatments does not significantly reduce the composite primary outcome in patients with HF and preserved ejection fraction (HFpEF), reported the phase 3 TOPCAT study. Topics: Heart Failure (HF) (Source: ESC News and Press)
Source: ESC News and Press - April 23, 2014 Category: Cardiology Source Type: news

PodMed: A Medical News Roundup From Johns Hopkins (with audio)
(MedPage Today) -- This week's topics include new treatments for hepatitis C, paternal obesity and autism risk, aspirin and preeclampsia, and spironolactone for one form of congestive heart failure. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - April 11, 2014 Category: Cardiology Source Type: news

TOPCAT in Print, With Quirks: Aldo-Blocker Misses in HFPEFTOPCAT in Print, With Quirks: Aldo-Blocker Misses in HFPEF
Spironolactone didn't show a primary-end-point gain in preserved-ejection-fraction heart failure. But there were glimmers of possible benefit along with a controversy about the trial's design. Heartwire (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 10, 2014 Category: Cardiology Tags: Cardiology News Source Type: news

Does Spironolactone Benefit Patients with HF and Preserved Systolic Function? (FREE)
By Harlan M. Krumholz, MD, SM Spironolactone showed no significant advantage over placebo among patients with heart failure and preserved systolic function in a New England Journal of Medicine study, but the case may not be closed.Some 3500 adults with symptomatic heart failure and a left … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - April 10, 2014 Category: Primary Care Source Type: news

TOPCAT Study Shows Spironolactone Did Not Reduce Primary Outcome, but Did Reduce Hospitalizations for Heart Failure
Spironolactone did not significantly reduce primary endpoint (Source: BWH News)
Source: BWH News - April 10, 2014 Category: Hospital Management Source Type: news

TOPCAT Study Shows Spironolactone Did Not Reduce Primary Outcome, but Did Reduce Hospitalizations for Heart Failure
Spironolactone did not significantly reduce primary endpoint (Source: BWH for Journalists)
Source: BWH for Journalists - April 10, 2014 Category: Research Source Type: news

TOPCAT Study Shows Spironolactone Did Not Reduce Primary Outcome, but Did Reduce Hospitalizations for Heart Failure
Spironolactone did not significantly reduce primary endpoint (Source: BWH News)
Source: BWH News - April 10, 2014 Category: Hospital Management Source Type: news

Spironolactone May Benefit Some HF Patients (CME/CE)
(MedPage Today) -- The TOPCAT trial of spironolactone for patients with heart failure and a preserved ejection fraction failed to meet its primary endpoint, but showed a modest reduction in heart failure hospitalizations with the drug, final results affirmed. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - April 10, 2014 Category: Cardiology Source Type: news

Troubled NHLBI TOPCAT Trial Disappoints
Although a significant portion of people with heart failure have preserved ejection fraction, none of the proven heart failure therapies has been shown to be beneficial in this important and growing heart failure subpopulation. Now a new NHLBI-funded study has failed to find a benefit in this group for spironolactone, which is a cornerstone of therapy for heart failure patients with reduced ejection fraction. But trial investigators and heart failure experts believe it is too early to dismiss hope that spironolactone and other aldosterone antagonists-- including Pfizer's Inspra (eplerenone)-- may eventually be found to wor...
Source: Forbes.com Healthcare News - April 9, 2014 Category: Pharmaceuticals Authors: Larry Husten Source Type: news

Enhancement of chemotherapy by prevention of tumor cell repair
The body naturally tries to repair lesions in the DNA of tumor cells, and thus reduces the efficacy of chemotherapy. Blocking the mechanisms for DNA repair would help to potentiate chemotherapy by reducing the resistance of cells to treatment. A team of scientists has discovered a new drug that inhibits repair: spironolactone, which seems likely to be used in the very short term as an adjuvant to chemotherapy. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - February 20, 2014 Category: Science Source Type: news

Enhancement of chemotherapy by prevention of tumor cell repair
(INSERM (Institut national de la santé et de la recherche médicale)) The body naturally tries to repair lesions in the DNA of tumour cells, and thus reduces the efficacy of chemotherapy. Blocking the mechanisms for DNA repair would help to potentiate chemotherapy by reducing the resistance of cells to treatment. A team directed by Frédéric Coin, Inserm Research Director in Strasbourg, has discovered a new drug that inhibits repair: spironolactone, which seems likely to be used in the very short term as an adjuvant to chemotherapy. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - February 20, 2014 Category: Biology Source Type: news

14p a day tablet could ease pain for millions of arthritis sufferers without dangerous side effects
Spironolactone, usually used for high blood pressure and heart failure, could help people with osteoarthritis. (Source: the Mail online | Health)
Source: the Mail online | Health - December 16, 2013 Category: Consumer Health News Source Type: news

TOPCAT: Aldo-Antagonist Falls Short but Impresses in HFPEFTOPCAT: Aldo-Antagonist Falls Short but Impresses in HFPEF
Spironolactone failed on the trial's primary end point, but its effect on HF hospitalizations has convinced some experts it's worth using in a disorder without other good drug options. Heartwire (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 19, 2013 Category: Cardiology Tags: Cardiology News Source Type: news

AHA: Decision on Spironolactone in HF a Toss-Up? (CME/CE)
DALLAS (MedPage Today) -- The TOPCAT trial evaluating spironolactone in patients with heart failure and preserved ejection fraction did not meet its primary endpoint, but there was some evidence of benefit, a researcher reported here. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - November 19, 2013 Category: Cardiology Source Type: news

New Study Shows Spironolactone Reduces Heart Failure Hospitalizations, But Not Mortality
Spironolactone reduces the risk of repeated hospitalizations for heart failure. (Source: BWH for Journalists)
Source: BWH for Journalists - November 18, 2013 Category: Research Source Type: news

New Study Shows Spironolactone Reduces Heart Failure Hospitalizations, But Not Mortality
Spironolactone reduces the risk of repeated hospitalizations for heart failure. (Source: BWH News)
Source: BWH News - November 18, 2013 Category: Hospital Management Source Type: news

Featured in NEJM Journal Watch: Spironolactone Mitigates Rosacea Risk (FREE)
By the NEJM Journal Watch Editors In a large population-based analysis, spironolactone users … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - November 5, 2013 Category: Primary Care Source Type: news

Race Tied to Outcomes with HF Drug (CME/CE)
(MedPage Today) -- African Americans with heart failure and reduced left ventricular output may not derive the same benefit from spironolactone as other ethnic groups, a post-hoc analysis of the randomized RALES trial found. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - August 16, 2013 Category: Cardiology Source Type: news

Spironolactone Improves Arrhythmogenic Substrate in HFSpironolactone Improves Arrhythmogenic Substrate in HF
Find out how this mineralocorticoid receptor antagonist reduces sudden cardiac death in patients with heart failure. Journal of Cardiovascular Electrophysiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 31, 2013 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

Spironolactone of Benefit in Resistant HypertensionSpironolactone of Benefit in Resistant Hypertension
Daytime blood pressure measured by 24-hour ambulatory blood-pressure monitoring was reduced by 8.9/3.7 mm Hg, report investigators. The data suggest that the addition of spironolactone might be beneficial in this hard-to-treat patient population already receiving multiple antihypertensive medications, they add. Heartwire (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 17, 2013 Category: Consumer Health News Tags: Cardiology News Source Type: news

Spironolactone provides benefit in resistant hypertension, small study shows
Daytime blood pressure measured by 24-hour ambulatory blood-pressure monitoring was reduced by 8.9/3.7 mm Hg, report investigators. The data suggest that the addition of spironolactone might be beneficial in this hard-to-treat patient population already receiving multiple antihypertensive medications, they add. (Source: theHeart.org)
Source: theHeart.org - June 17, 2013 Category: Cardiology Source Type: news

Bayer's New MRA Passes First TestBayer's New MRA Passes First Test
Patients treated with the drug, known only as BAY94-8862 at the moment, had a significantly lower risk of hyperkalemia than patients treated with spironolactone, as well as a lower risk of worsening renal failure. The drug also reduced BNP levels as much as spironolactone. Heartwire (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 31, 2013 Category: Consumer Health News Tags: Cardiology News Source Type: news

New mineralocorticoid-receptor antagonist passes in phase 2 study
Patients treated with the drug, known only as BAY94-8862 at the moment, had a significantly lower risk of hyperkalemia than patients treated with spironolactone, as well as a lower risk of worsening renal failure. The drug also reduced BNP levels as much as spironolactone. (Source: theHeart.org)
Source: theHeart.org - May 30, 2013 Category: Cardiology Source Type: news

BAY 94-8662 shows promise in HF patients with reduced renal function.
BAY 94-8662 - a next generation mineralocorticoid receptor antagonist (MRA) - is at least as effective as spironolactone in reducing biomarkers of hemodynamic stress, and associated with a lower incidence of hyperkalaemia and worsening renal function (WRF), reported the phase II ARTs study. Read more Topics: Heart Failure (HF) (Source: ESC News and Press)
Source: ESC News and Press - May 26, 2013 Category: Cardiology Source Type: news

Digoxin toxicity: check the magnesium level!
3 out of 5 stars Digoxin Toxicity with Normal Digoxin and Serum Potassium Levels: Beware of Magnesium, the Hidden Malefactor. Rao MPR et al. J Emerg Med 2013 May 16 [Epub ahead of print] Abstract This case report from Oman describes at 66-year-old woman (inexplicably described as “elderly”) who presented to hospital with one day of nausea, vomiting, abdominal distress, and palpitations. Her medications included furosemide, spironolactone, digoxin, carvedilol, lisinopril, metformin, and calcium. Initial EKGs showed evidence of junctional tachycardia and digoxin effect. The treating physicians initially cons...
Source: The Poison Review - May 23, 2013 Category: Toxicology Authors: Leon Tags: Medical digitalis digoxin toxicity hypomagnesemia magnesium potassium Source Type: news

Benefits of diastolic function improvement in heart failure questioned
The importance of left ventricular diastolic function improvement in patients with heart failure with preserved ejection fraction has been questioned, after researchers found that treatment with spironolactone resulted in some functional improvements but failed to impact on patients’ exercise capacity. (Source: MedWire News - Cardiology)
Source: MedWire News - Cardiology - March 4, 2013 Category: Cardiology Source Type: news

RCT: Effect of spironolactone on diastolic function and exercise capacity in diastolic heart failure (Aldo-DHF)
Source: JAMA Area: News Diastolic heart failure (heart failure with preserved ejection fraction) is a common condition affecting more than half of the total heart failure population but without established therapy. Furthermore, aldosterone stimulation may contribute to its progression.   The Aldo-DHF trial, a multicentre, prospective, randomised, double-blind, placebo-controlled trial, evaluated the effect of long-term spironolactone on diastolic function and exercise capacity in patients with diastolic heart failure.   The study randomised 422 ambulatory patients (mean age, 67 years; 52% female) with ch...
Source: NeLM - Cardiovascular Medicine - February 27, 2013 Category: Cardiology Source Type: news

Heart Failure Drug May Only Help Heart's Function, Not Symptoms
Spironolactone didn't boost treadmill test results, quality of life in one form of condition, study finds (Source: WebMD Health)
Source: WebMD Health - February 26, 2013 Category: Consumer Health News Source Type: news

Spironolactone Disappoints in Preserved-EF HF: Aldo-DHFSpironolactone Disappoints in Preserved-EF HF: Aldo-DHF
Aldosterone blockade didn't produce the outcomes that matter most to patients, despite one benefit in the 422-patient study that was at least encouraging. A large mortality trial is on the way. Heartwire (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 26, 2013 Category: Consumer Health News Tags: Cardiology News Source Type: news

Mixed Results For Spironolactone In Heart Failure With Preserved Ejection Fraction
Although the mineralocorticoid receptor antagonists (MRAs) spironolactone and eplerenone (Inspra, Pfizer) have been shown to be beneficial in patients with heart failure (HF) with reduced ejection fraction (EF), their role in heart failure patients with preserved EF has not been tested until now. Now the results of the Aldo-DHF (Aldosterone Receptor Blockade in Diastolic Heart Failure), published in the Journal of the American Medical Association, demonstrate that although the treatment works as expected to improve diastolic function in this patient population, no clinical benefits were observed in association with th...
Source: Forbes.com Healthcare News - February 26, 2013 Category: Pharmaceuticals Authors: Larry Husten Source Type: news

Spironolactone disappoints in preserved-EF heart failure: Aldo-DHF in print
Aldosterone blockade didn't produce the outcomes that matter most to patients, despite one benefit in the 422-patient study that was at least encouraging. A large mortality trial is on the way. (Source: theHeart.org)
Source: theHeart.org - February 26, 2013 Category: Cardiology Source Type: news

Long-Term Use Of Medication May Improve Heart Function, But Does Not Improve Symptoms, Quality Of Life For Heart Failure Patients
Among patients with heart failure with preserved ejection fraction, long-term treatment with the medication spironolactone improved left ventricular diastolic function but did not affect maximal exercise capacity, patient symptoms, or quality of life, according to a study appearing in the February 27 issue of JAMA... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - February 26, 2013 Category: Consumer Health News Tags: Cardiovascular / Cardiology Source Type: news

Heart Failure Drug May Only Help Heart's Function, Not Symptoms
Spironolactone didn't boost treadmill test results, quality of life in one form of condition, study finds Source: HealthDay Related MedlinePlus Page: Heart Failure (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - February 26, 2013 Category: Consumer Health News Source Type: news

Drug Has Mixed Results in Diastolic HF (CME/CE)
(MedPage Today) -- In patients with heart failure with preserved ejection fraction, spironolactone improved left ventricular diastolic function but did not affect clinical status, the Aldo-DHF trial showed. (Source: MedPage Today State Required CME)
Source: MedPage Today State Required CME - February 26, 2013 Category: Consumer Health News Source Type: news

Spironolactone Improves Diastolic Function in CHF, but Not Symptoms or Exercise Capacity
(Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - February 26, 2013 Category: Primary Care Tags: Medical News Source Type: news

Doubling down on RAAS blockade in HF? Aldosterone antagonists, not ARBs, says meta-analysis
For patients with symptomatic systolic heart failure on ACE inhibitors, further renin-angiotensin-aldosterone system suppression with spironolactone (or eplerenone) should help clinically with reasonable safety; the same can't be said for ARBs. (Source: theHeart.org)
Source: theHeart.org - December 24, 2012 Category: Cardiology Source Type: news